Status
Conditions
Treatments
About
This study is based on the hypothesis that the pharmacokinetics of antibiotics in children is different from adults. Cephalosporins and macrolide antibiotics are the common drugs for children with community acquired pneumonia, the investigators aim to study the population pharmacokinetics of cephalosporins and macrolide antibiotics in children receiving the drug for treatment of community acquired pneumonia, and to correlate it with treatment effectiveness and incidence of adverse effects.
Potential Impact: This novel knowledge will allow better and more rational approaches to the treatment of community acquired pneumonia. It will also set the foundation for further studies that will be able to test improved therapies that may increase treatment response in vulnerable children.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Children 1-18 years old of both sexes, with a diagnosis of community acquired pneumonia and eligible for treatment with cephalosporins and macrolide antibiotics, as per current treatment protocols.
Community acquired pneumonia diagnostic criteria: meet any one of the 1-4 following items plus the fifth item:
Informed consent signed by the parents, and consent or assent of the patients (according to age and consenting capacity).
Exclusion criteria
Loading...
Central trial contact
A-Dong Shen, Master
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal